The multi-kinase pathway inhibitor sorafenib, active against RAS/RAF, c-kit, VEGFR, PDGFR, and FLT3, was previously investigated in addition to chemotherapy induction and showed no superior effect in AML patients older than 60 years [25], but improved event-free survival in younger patients, albeit with increased toxicity [26]. This evidence concerns the gene KDR and acute myeloid leukemia.